TNFRSF25 and B-cell chronic lymphocytic leukemia: In conclusion, we propose a novel regulatory function for TL1A/DR3 that, differentially expressed in relation with clinical stage, may alter the balance between cell proliferation and death, influencing CLL physiopathology and clinical outcome.